Institute for OneWorld Health Offers Global Health Experts for Commentary on Timely Healthcare Topics.

SAN FRANCISCO -- Institute for OneWorld Health:

WHAT     Global health will be headlining the news beginning the first
         week of November. From a national public television series,
         titled Rx for Survival, to an international Global Health
         Summit, several prominent public health organizations are
         encouraging Americans to learn more about and seek out
         solutions to global health problems.

         The Institute for OneWorld Health, the first U.S. nonprofit
         pharmaceutical company, is pursuing a mission of developing
         safe, effective, affordable new medicines for diseases
         affecting people in the developing world. In five years,
         OneWorld Health has completed a clinical trial for visceral
         leishmaniasis (VL) in India, received orphan drug status
         from the FDA for its drug, paromomycin, to treat VL, and
         made plans to submit paromomycin for approval with the
         Indian government.

         These are the diseases targeted by OneWorld Health's
         pipeline:

         Visceral leishmaniasis (VL), also known as kala azar, is
         fatal if left untreated. Of the 500,000 new cases of VL
         occurring annually, 90 percent are in five countries:
         Bangladesh, India, Nepal, Brazil and the Sudan.

         Diarrheal diseases account for approximately 2 million deaths
         annually in children under the age of 5. Disease and death
         caused by diarrhea is a worldwide problem, but is especially
         prevalent in developing countries.

         Malaria causes nearly 600 million new infections, more than
         300 million acute illnesses and up to 3 million deaths
         annually. Malaria is a disease of poverty and is endemic in
         nearly 100 countries worldwide, notably in sub-Saharan
         Africa, where 90 percent of deaths occur, mostly among young
         children.

         Chagas disease infects an estimated 10-14 million people
         within the 19 endemic countries of Central and South
         America. And, some 100 million people (about 25 percent of
         the population of Latin America) are reportedly at risk of
         acquiring Chagas disease.

         More information is available at www.oneworldhealth.org.

WHEN     Interviews can be arranged as requested.